Kiadis Pharma NV (FRA:K3P) ROCE % : -1,030.90% (As of Dec. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kiadis Pharma NV's annualized ROCE % for the quarter that ended in Dec. 2020 was -1,030.90%.

Kiadis Pharma NV ROCE % Historical Data

The historical data trend for Kiadis Pharma NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV ROCE % Chart

Kiadis Pharma NV Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

ROCE %

Get a 7-Day Free Trial

-41.06

-45.74

-46.06

-80.61

-584.06

Kiadis Pharma NV Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20
ROCE %	Get a 7-Day Free Trial											-42.69	-54.23	-65.10	-74.13	-1,030.90

Kiadis Pharma NV ROCE % Calculation

Kiadis Pharma NV's annualized ROCE % for the fiscal year that ended in Dec. 2020 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2020 )		(A: Dec. 2019 )		(A: Dec. 2020 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2020 )		(A: Dec. 2019 )		(A: Dec. 2020 )
	=	-79.786	/	( ( (79.502 - 30.259)	+	(62.762 - 84.684) )	/ 2 )
	=	-79.786	/	( (49.243	+	-21.922)	/ 2 )
	=	-79.786	/	13.6605
	=	-584.06 %

Kiadis Pharma NV's ROCE % of for the quarter that ended in Dec. 2020 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2020 )		(Q: Jun. 2020 )		(Q: Dec. 2020 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2020 )		(Q: Jun. 2020 )		(Q: Dec. 2020 )
	=	-124.26	/	( ( (68.122 - 22.093)	+	(62.762 - 84.684) )	/ 2 )
	=	-124.26	/	( ( 46.029	+	-21.922 )	/ 2 )
	=	-124.26	/	12.0535
	=	-1,030.90 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2020) EBIT data.

Kiadis Pharma NV (FRA:K3P) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kiadis Pharma NV ROCE % Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiadis Pharma NV (FRA:K3P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (FRA:K3P) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP

Website

https://www.kiadis.com

Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (FRA:K3P) Headlines

No Headlines